New diabetes combo shows promise in blood sugar control
NCT ID NCT01026194
First seen Jan 06, 2026 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study tested a new drug, MP-513 (Teneligliptin), added to a standard diabetes pill (pioglitazone) in 204 Japanese adults with type 2 diabetes. The goal was to see if the combination improved blood sugar control over 12 weeks, with a follow-up up to 52 weeks. Participants had to be on diet/exercise and taking pioglitazone for at least 16 weeks before joining.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Shinjukuku, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.